Status:
WITHDRAWN
Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients
Lead Sponsor:
Korea Cancer Center Hospital
Conditions:
Cervical Neoplasms
Eligibility:
FEMALE
Phase:
PHASE2
Brief Summary
The standard postoperative treatment for patients with cervical cancer who had high-risk factors is chemoradiation. Generally, weekly cisplatin or 5FU+cisplatin every 3 week have been used as chemothe...
Detailed Description
Cervical carcinoma is one of the most common gynecologic cancers worldwide. The prognosis of cervical cancer is favorable, with around 80-90% 5-year survival rate in early stage disease. However, adva...
Eligibility Criteria
Inclusion
- cervical cancer
- underwent radical hysterectomy
- non-small cell type
- FIGO stage 1B - 2A
- have one or more risk factors (lymph node involvement, resection margin involvement, parametrial involvement)
- GOG performance status 0 - 2
Exclusion
- Previous history of chemotherapy or radiation
- History of other cancer
- Hypersensitivity to platinum agents
- Pregnancy
- Serious medical disease
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2012
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00950261
Start Date
January 1 2009
End Date
May 1 2012
Last Update
August 13 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea Institute of Radiological & Medical Sciences
Seoul, South Korea, 139-706